Pain

Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816, that strongly and selectively binds with and activates the alpha3 glycine pain receptor. Activation...

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced a major step forward in its program to develop the first cannabinoid-derived pain treatment targeting activation of alpha3 glycine receptors. When activated, the alpha3 glycine...

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced the formation of a Strategic & Scientific Advisory Board with three key appointments: Professor Joseph Lynch, Ph.D.; Dr. Li Zhang; and Professor Hanns Ulrich Zeilhofer. The Strategic...

Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it is has begun development of a novel cannabinoid-based compound for the treatment of acute and chronic pain. Patents for this compound have been...